Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Banner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 6, 2012
7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: novel and highly selective protein tyrosine phosphatase 1B inhibitorsAdrian Wai-Hing Cheung, Bruce Banner, Jolly Bose, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, selective MCH-1 receptor antagonistsShawn D Erickson, Bruce Banner, Steven Berthel, et al.
Journal of Medicinal Chemistry|April 10, 2014
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemiaMartha J Kelly, Sherrie Pietranico-Cole, J Douglas Larigan, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|November 6, 2012
7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: novel and highly selective protein tyrosine phosphatase 1B inhibitorsAdrian Wai-Hing Cheung, Bruce Banner, Jolly Bose, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Potent, selective MCH-1 receptor antagonistsShawn D Erickson, Bruce Banner, Steven Berthel, et al.
Journal of Medicinal Chemistry|April 10, 2014
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemiaMartha J Kelly, Sherrie Pietranico-Cole, J Douglas Larigan, et al.
Pageof 1